Form 4: Iovance Biotherapeutics COO Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding, resulting in a net change in his holdings.
Summary
- Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
- On December 2, 2024, 3,516 restricted stock units (RSUs) vested, converting into common stock.
- To cover mandatory tax withholding, 1,784 shares were withheld by the company at a price of $9.07 per share.
- Following these transactions, Bilinsky's direct holdings decreased to 57,539 shares of common stock.
- He also holds 17,581 unvested restricted stock units.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but rather a standard process.
Future Outlook
The remaining restricted stock units will vest in equal quarterly installments.
Industry Context
This is a routine filing related to executive compensation and is common for publicly traded companies. It provides transparency into the stock ownership of company insiders.
Comparison to Industry Standards
- The vesting of restricted stock units is a standard practice in executive compensation across the biotechnology industry.
- Tax withholding upon vesting is also a common procedure to ensure compliance with tax regulations.
- Similar filings are regularly made by executives at comparable companies such as Kite Pharma, Juno Therapeutics, and Adaptimmune.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in insider ownership, but is not a market transaction.
- The transaction has no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/02/2024 | Date of the restricted stock unit vesting and subsequent stock transactions. |
| 12/04/2024 | Date the Form 4 was signed by Igor Bilinsky. |
Keywords
Form 4, Iovance Biotherapeutics, Insider Trading, Restricted Stock Units, Stock Vesting, Beneficial Ownership, IOVA, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.